Centralized administration is critical for efficient project management, coordination, and execution. Core A (Administrative Core) will provide all the logistic, scientific, managerial, financial, and biostatistics support to facilitate and to coordinate the studies described in this Consortium. The Administrative Core will ensure that all the Projects and Cores function optimally and adhere to the timelines described in the individual sections of this grant. The Administrative Core will establish a Scientific Leadership Committee as the primary decision making committee for this Consortium, organize conference calls every two weeks and regular in-person meetings, maintain regulatory approvals, provide fiscal and logistic oversight, manage subcontracts, and coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials. This detailed administration and management structure will ensure that all the studies remain focused on the overall objective to evaluate the early events of acute mucosal SIV/SHIV infection and the capacity of vaccines to impact these events. To accomplish these goals, we propose the following five Specific Aims: 1. To coordinate communications, interactions, and operations among investigators, Projects, and Cores to facilitate the overall progress and goals of this Consortium; 2. To ensure and to maintain regulatory compliance; 3. To provide detailed financial oversight and management; 4. To coordinate meetings with the Scientific Advisory Board and DAIDS Program Officials;and 5. To provide biostatistics support for all Projects and Cores.
A major roadblock is our current lack of understanding of the earliest events following mucosal HIV-1 exposure and the potential vaccine-elicited immune responses that might be able to impact these events. This consortium brings together leaders in the nonhuman primate and HIV-1 vaccine fields to address these questions. To accomplish these goals, a centralized Administrative Core is proposed to coordinate the efforts of the projects and cores.
|Aid, Malika; Abbink, Peter; Larocca, Rafael A et al. (2017) Zika Virus Persistence in the Central Nervous System and Lymph Nodes of Rhesus Monkeys. Cell 169:610-620.e14|
|Barouch, Dan H; Thomas, Stephen J; Michael, Nelson L (2017) Prospects for a Zika Virus Vaccine. Immunity 46:176-182|
|Abbink, Peter; Larocca, Rafael A; Visitsunthorn, Kittipos et al. (2017) Durability and correlates of vaccine protection against Zika virus in rhesus monkeys. Sci Transl Med 9:|
|Ackerman, Margaret E; Barouch, Dan H; Alter, Galit (2017) Systems serology for evaluation of HIV vaccine trials. Immunol Rev 275:262-270|
|McMichael, Andrew J; Picker, Louis J (2017) Unusual antigen presentation offers new insight into HIV vaccine design. Curr Opin Immunol 46:75-81|
|Keele, Brandon F; Li, Wenjun; Borducchi, Erica N et al. (2017) Adenovirus prime, Env protein boost vaccine protects against neutralization-resistant SIVsmE660 variants in rhesus monkeys. Nat Commun 8:15740|
|Zeng, Ming; Smith, Anthony J; Shang, Liang et al. (2016) Mucosal Humoral Immune Response to SIVmac239?nef Vaccination and Vaginal Challenge. J Immunol 196:2809-18|
|Liu, Jinyan; Ghneim, Khader; Sok, Devin et al. (2016) Antibody-mediated protection against SHIV challenge includes systemic clearance of distal virus. Science 353:1045-1049|
|Martinez-Navio, José M; Fuchs, Sebastian P; Pedreño-López, Sònia et al. (2016) Host Anti-antibody Responses Following Adeno-associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys. Mol Ther 24:76-86|
|Stephenson, Kathryn E; Neubauer, George H; Bricault, Christine A et al. (2016) Antibody Responses After Analytic Treatment Interruption in Human Immunodeficiency Virus-1-Infected Individuals on Early Initiated Antiretroviral Therapy. Open Forum Infect Dis 3:ofw100|
Showing the most recent 10 out of 52 publications